Quanifen

Quick links to important sections

Quanifen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quanifen

Property Description
Active ingredient Fenbendazole, Praziquantel
Form Oral tablet
Pharmacological class Anthelmintic
General purpose Management of mixed parasitic infections
Origin Synthetic

What Kind of Medicine is Quanifen? (Identity and Classification)

Quanifen is a synthetic combination antiparasitic veterinary medicinal product used primarily for companion animals, specifically dogs and cats. It is structurally classified as an anthelmintic, which means it is a medicine designed to expel or destroy parasitic worms. This combination is a fixed-dose drug intended for the simultaneous treatment of infections caused by different species of helminthes in the target species.

This medication is presented in the pharmaceutical preparation of an oral tablet. Quanifen is manufactured by Chanelle Pharmaceuticals Manufacturing Limited and is supplied as a Veterinary Medicinal Product subject to veterinary prescription. This positioning establishes it as a professionally managed broad-spectrum dewormer, typically used in a clinical setting to manage common parasite issues.


Quanifen Composition: A Dual-Action Formulation (Ingredients and Type)

Quanifen is a fixed combination product that relies on the synergistic action of two main active ingredients: Fenbendazole and Praziquantel. The selection of these two compounds is strategic: Fenbendazole is classified as a benzimidazole carbamate, while Praziquantel is a pyrazine isoquinoline derivative.

This dual composition provides broader coverage than monotherapy. Benzimidazole and isoquinoline compounds are key agents in the management of helminthiasis, demonstrating high efficacy against different types of parasites.


General Purpose and Broad-Spectrum Benefit (Therapeutic Focus)

The general purpose of Quanifen is the effective management and elimination of mixed parasitic infections in target animals, such as an outbreak involving both roundworms (nematodes) and tapeworms (cestodes). The drug’s broad-spectrum nature means it is uniquely formulated to act against both groups simultaneously. This results in the complete elimination of established parasitic populations, helping to restore the animal’s physiological health by clearing the system of infestation.

Regulatory References

  1. European Public Assessment Reports (EPARs)

What side effects are possible with Quanifen?

Official Adverse Reactions and Frequency Classification

The safety profile for Quanifen, a combination of Fenbendazole and Praziquantel, is defined by adverse reactions classified according to their occurrence frequency in treated patients, as documented in regulatory sources.

Adverse reactions are primarily categorized as Uncommon, meaning they are reported in more than 1 but less than 10 animals in every 1,000 treated. These effects are classified across two main system-organ classes:

  • Gastrointestinal Tract: Documented reactions include vomiting and diarrhea.
  • Systemic and General Disorders: The official label lists lethargy.

No adverse reactions are explicitly designated as 'Serious' in the available official regulatory documents for the equivalent medicinal product. All side effect descriptions are taken directly from the formal regulatory documentation.


Safety-Related Restrictions and Constraints

The medicine is subject to mandatory limitations and safety constraints defined within the official prescribing information:

  • Contraindications: Quanifen must not be used in animals with known hypersensitivity to either active ingredient, or in those with pre-existing conditions such as severe systemic disease or compromised liver function.
  • Population Limitations: Safety has not been established for animals younger than six weeks of age. For pregnant animals, use is not recommended during the first two trimesters, but it is permitted during the last third of gestation.

These constraints establish the specific health states and age limitations under which the product should not be administered, based on regulatory evaluation.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Quanifen

This section describes the overdose profile for Quanifen (Fenbendazole/Praziquantel) as documented in official government regulatory sources.


Documented Overdose Manifestations

Overdose cases documented in regulatory studies primarily presented with transient, non-severe manifestations. Signs observed following administration of doses three to five times (ge 3 imes to ge 5 imes) the recommended amount include transient diarrhoea, loose faeces, and occasional vomiting. Behavioral signs documented in young animals included crying and restlessness in puppies, as well as excessive salivation in dogs and puppies. Inappetence was specifically observed in cats at the higher dose level.


Required Emergency Actions and Management

Domain Regulatory Statement
Severity Classification Not classified as severe or life-threatening; effects noted as transient.
Antidote Information No specific antidote is described or listed in the official labeling.
Required Action Signs of overdose should be treated symptomatically.
Immediate Help Required The official documentation does not contain an explicit instruction or mandatory phrasing requiring immediate medical attention.

The regulatory profile directs care toward symptomatic and supportive treatment for the observed effects. No specific monitoring or hospitalization requirements are documented.

Therapeutic Uses of Quanifen

What Quanifen Treats: Main Uses and Benefits

Quanifen is commonly used for managing established mixed parasitic infections, applying across domains where additional symptomatic support is needed. The therapeutic domain includes use across both major groups of helminths: tapeworms (cestodes), including Taenia and Echinococcus species, and a variety of roundworms (nematodes), such as Toxocara, hookworms, and whipworms. This medication is relevant in clinical situations where parasitic infection has caused symptoms related to systemic imbalance.

It is used for managing symptom clusters like chronic or acute diarrhea, vomiting, and the systemic consequences of infection such as weight loss and ill thrift. When applied in appropriate clinical contexts, the drug may assist with maintaining functional stability and supports general well-being during symptomatic phases.

“This approach may be part of symptomatic management for infections and contributes to easing the overall symptom load.”

Beyond treating active infections, Quanifen is applied in scenarios where additional management of discomfort is required for proactive parasitic control, such as integration into routine deworming programs. It is also commonly used across specific use-relevant groups, including puppies, kittens, and pregnant females (during the last third of gestation), to manage parasitic manifestations relevant to these patient groups.


Quick Fact: Relevant in Conditions Involving Gastrointestinal Distress This medication supports patients during episodes of heightened discomfort, which may assist with maintaining functional stability when symptoms become more noticeable.

Regulatory References

  1. HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

The official regulatory eligibility for Quanifen is strictly defined by the animal's physiological state, age, and existing sensitivities. Use is contraindicated (absolutely prohibited) in several key population groups.

This includes all animals with a known hypersensitivity to the active ingredients, Fenbendazole or Praziquantel, or any excipients.

Age and Gestation-Based Prohibitions

Age and weight restrictions are mandatory: the medicine must not be used in kittens less than eight weeks of age or in puppies under two weeks of age or those weighing less than 0.5 kg.

Gestation status also determines eligibility. Quanifen is contraindicated in all pregnant cats. For dogs, it is prohibited before day 39 of pregnancy. Use is only conditionally permitted in pregnant bitches during the last third of gestation, requiring a mandatory veterinary benefit/risk assessment.

Conversely, use is permitted in both lactating bitches and queens.

Official labeling does not document specific restrictions based on hepatic or renal impairment.

What should I know about interactions with other medicines?

The official interaction profile for the combination veterinary medicine Quanifen (Fenbendazole / Praziquantel) is strictly defined by the content provided in government regulatory documentation. The authoritative Summary of Product Characteristics (SmPC) explicitly notes the status of the product's interactions with other substances in the section dedicated to co-administration.


Official Regulatory Interaction Status

Interaction Scope: The official label for Quanifen states that no specific interactions with other medicinal products or substances are known. This regulatory finding confirms the absence of documented effects for all major interaction categories.

Interaction Classification (High-Level) Regulatory Status
Formal Contraindications None documented
Pharmacokinetic Interactions (CYP/Transporter) None known
Pharmacodynamic Interactions None known
Timing or Separation Requirements None documented
Food/Substance Interactions None documented

Interaction-Related Restrictions: The regulatory information does not define any interactions that necessitate the separation of doses, nor does it list any medicinal products or substances that are formally prohibited or contraindicated for co-administration.

Connection to the overall interaction profile: The interaction structure is entirely governed by the official regulatory statement of no known interactions with other medicinal products or substances. This position removes the requirement for formal interaction risk classifications or administrative constraints in the regulatory labeling.

Mechanism of Action

How Quanifen Works

The mechanism of Quanifen is defined by the complementary actions of its two active ingredients, Fenbendazole and Praziquantel, each targeting distinct and essential biological systems in different classes of parasitic worms.

The Fenbendazole component acts as an inhibitor by binding to beta-tubulin subunits in the nematode's cells. This interaction prevents the formation of microtubules, severely compromising the parasite's cellular structure and the transport of nutrients. The cascade culminates in irreversible metabolic failure and cellular collapse of the nematode.

The Praziquantel component functions as a modulator to cause a rapid, uncontrolled increase in calcium ion ( Ca^2+) permeability across the tapeworm's (cestode's) membranes. This massive ion influx triggers immediate, severe spastic paralysis and rapid destruction of the parasite's protective outer layer, making it vulnerable to elimination.

The dual mechanism is essential because the mechanisms have target specificity limitations against different worm classes. The coordinated attack ensures the simultaneous physiological disruption of both major worm classes, resulting in the elimination of the parasitic burden.

Dosage and Administration Information

How to Use Quanifen

Quanifen is intended solely for oral administration and is administered as an oral tablet. The standardized use of this medication is governed by a weight-based dosing principle that mandates precise calculation for every course of treatment. The therapeutic regimen requires the delivery of a combined dose of 50 mg Fenbendazole per kilogram of body weight and 5 mg Praziquantel per kilogram of body weight, which is achieved by administering the corresponding number of tablets or half-tablets.

For the management of established parasitic infections, the standard use is a single administration course. For routine parasitic control, the medication is generally used on an intermittent schedule, such as administration every three months, as part of a long-term plan.

Administration is flexible with regard to feeding; the tablets may be given with or without food, and there is no requirement for the animal to fast before or after treatment. The tablet can be given directly or mixed into a small amount of food.

Instructions address use in certain groups: the product is approved for use in puppies and kittens from two weeks of age, provided the minimum weight for accurate dosing is met. It is also approved for use in pregnant females during the final third of gestation. The mandatory procedural condition for all use is the accurate determination of body weight prior to dosing to ensure the correct amount of active ingredient is delivered.

Recent Clinical Evidence

Quanifen: Recent Clinical Evidence


Evidence for Use in Mixed Parasitic Infections

Research was studied for use in companion animals for conditions involving periods of heightened symptoms related to mixed internal parasitic infections (nematodes and cestodes). Studies was evaluated in structures such as Controlled Efficacy Field Trials, sometimes randomized. These trials monitored outcomes related to systemic imbalance. Research highlights changes measured during the study period, quantified by assessing parasite clearance rates and tracking changes in Fecal Egg Counts (EPG). Findings describe patterns observed that were reviewed by regulatory bodies to support the authorized indications for this broad spectrum of use.


Endpoints and Measurement in Clinical Trials

The research explored methods to measure how the medicine was evaluated in the study populations. Primary assessments focused on whether a treated animal reached a post-treatment negativity status on various diagnostic tests, which was studied for indicating the absence of detectable parasite eggs. These measurements are relevant in evidence describing how outcomes were tracked following the observed clearance of the underlying parasitic population. Further research included Bioequivalence Studies, which measured plasma concentrations of the active ingredients over defined time intervals.


Evidence in Special Populations

The research has explored the use of Quanifen across certain special populations, although data for certain groups remain insufficient. Studies was observed in puppies and kittens and pregnant bitches (dogs in the final third of gestation). The data show patterns related only to the specific special populations studied, and information for other groups, such as pregnant cats, certainty remains low.


Long-Term Studies and Follow-up Durations

The follow-up durations used in the core efficacy trials were limited. Most studies assessed outcomes within a short-term period (typically 7 to 14 days) to explore the observed reduction in parasite counts. Long-term effects are not fully established regarding the sustained absence of infection over many months. The evidence provides insight into short-term changes, but there is limited information for long-term outcomes or the durability of the initial response.


Gaps and Uncertainty in the Research Record

The research base highlights what is still uncertain. One key area is that many individual field trials utilized modest sample sizes. The research landscape is also limited by a lack of comparative evidence or routine surveillance programs to track the development of anthelmintic resistance. Research has also explored how different fecal diagnostic techniques used to measure outcomes may yield discrepant results, which contributes to uncertainty when interpreting the post-treatment status.

Key Studies & References

  1. HPRA Summary of Product Characteristics for Quanifen (Fenbendazole/Praziquantel)

Frequently Asked Questions (FAQ)

Common questions about Quanifen (FAQ)


Q: How quickly does Quanifen typically start working?

Studies on the way the ingredients are processed by the body (pharmacokinetics) indicate that one active ingredient is absorbed quickly, reaching its highest concentration within about an hour. The other ingredient is absorbed slower, reaching its highest level in roughly 14 hours. Therefore, while the action starts relatively quickly, full observable results, like parasite clearance, are typically evaluated over several days.


Q: How long does the effect of a single dose of Quanifen last?

Official information on how the active ingredients are metabolized indicates they are quickly processed and eliminated from the body. Following a single administration, the active components are cleared from the system, for the most part, within 24 to 72 hours.


Q: Can I take simple pain relievers while using Quanifen?

The official regulatory interaction status states that no specific interactions with other medicinal products or substances are known. However, regulatory bodies generally caution against the concurrent use of the anthelmintic ingredients in Quanifen with other specific types of deworming compounds, such as piperazine.


Q: What is the official recommended use period for Quanifen?

Official instructions describe two main approaches for using the medicine. For established infections, the standard is a single administration course. For routine parasite control, official guidance describes an intermittent schedule, often used every three months, as part of a long-term plan.


Q: What is the difference between Quanifen and its main competitor, name-X?

Official regulatory bodies do not provide comparative claims and will not state that any one product is superior to another. The labeling is restricted to defining Quanifen's approved composition and intended purpose only, without making comparisons to other medicines.


Q: What should I do before starting Quanifen?

According to the official product information, the mandatory procedural condition before administering the product is the accurate determination of body weight. This step is implemented to ensure the correct amount of active ingredient is delivered.


Q: Is Quanifen the same as other similar-sounding medications?

Official documents define Quanifen as a fixed combination veterinary product. It contains two specific active ingredients, Fenbendazole and Praziquantel, formulated together in a specific ratio. Other medicines that sound similar may contain different ingredients or a different mix of compounds.


Q: What if I take Quanifen, and it doesn't seem to be working?

Regulatory documents note that a potential lack of efficacy has been reported in specific phases of parasitic infection. If the expected therapeutic results are not observed after treatment, such circumstances are generally reviewed by the prescribing professional.


Q: Are there any common foods to avoid while using Quanifen?

Official labeling states that no specific interactions with common foods or substances are known that would necessitate avoidance or specific timing. The medicine may be administered flexibly, either with or without food.


Q: Can Quanifen affect the results of lab tests?

There is no regulatory statement that this product directly interferes with general routine diagnostic lab tests. Clinical trials utilize specific diagnostic measurements to evaluate the treatment’s effectiveness.


Q: Do many people experience a rash with Quanifen?

The official documentation lists specific effects classified as uncommon adverse reactions (reported in 1 to 10 animals per 1,000 treated), including vomiting, diarrhea, and lethargy. Rash is not among those listed for the target species.


Q: Why might a person need to stop taking Quanifen suddenly?

Official safety constraints state that the medicine is strictly contraindicated (must not be used) in animals with known hypersensitivity to the active ingredients. The presence of a severe, rapid adverse reaction would be a circumstance requiring professional assessment regarding cessation of use.


Q: Does Quanifen interact with birth control pills?

Official product information classifies Quanifen as a veterinary medicinal product authorized for use only in dogs and cats. Interactions with human medications such as birth control pills are therefore irrelevant to its official regulatory use.


Q: Can I take vitamins or minerals with Quanifen?

The official labeling states that no specific interactions with other medicinal products or substances are known. This position indicates the absence of documented restrictions for co-administration with other substances like vitamins or minerals.


Q: Do official prescribing guides mention any necessary monitoring while on Quanifen?

The official instructions mandate the accurate determination of body weight prior to dosing. Routine clinical monitoring beyond this initial check is not typically specified, particularly for a single-dose treatment regimen.


Q: Is it important to check my blood pressure while taking Quanifen?

Official product information classifies Quanifen as a veterinary medicinal product authorized for use only in dogs and cats. Human health monitoring requirements, such as checking blood pressure, are irrelevant to its official use.


Q: Can Quanifen affect your sleep schedule?

The official adverse reaction classification lists lethargy, which is classified as an uncommon systemic effect. Insomnia or other sleep schedule disturbances are not listed in the officially documented adverse reactions.


Q: Is Quanifen used for acute issues or chronic management?

Official instructions support the use of Quanifen in both contexts. A single administration course is the standard for treating an established, acute infection, and an intermittent schedule is used for routine long-term control.


Q: Is it normal to feel a bit dizzy after starting Quanifen?

The official documentation lists specific effects classified as uncommon adverse reactions, including vomiting, diarrhea, and lethargy. Dizziness is not among those listed for the target species.


Q: Are there specific symptoms that mean I should call a professional right away while on Quanifen?

The product is strictly contraindicated for animals with known hypersensitivity to the active ingredients. Any symptoms suggestive of a severe, rapid allergic response are typically circumstances that require immediate professional assessment.


Q: Does Quanifen affect your ability to drive?

Official product information classifies Quanifen as a veterinary medicinal product authorized for use only in dogs and cats. Human safety concerns, such as the ability to drive, are irrelevant to its official regulatory use.


Q: Can you take Quanifen if you are generally healthy?

The official label prohibits use in animals with pre-existing conditions such as severe systemic disease or compromised liver function. This establishes that use is intended for otherwise generally healthy or non-severely ill animals.


Q: Is it common for people to have mild nausea with Quanifen?

The official documentation lists specific effects classified as uncommon adverse reactions, including vomiting, diarrhea, and lethargy. Nausea is not among those listed, although vomiting is listed as a potential uncommon effect.

How should Quanifen be stored and disposed of?

The storage and disposal of Quanifen must strictly follow the requirements documented in its official regulatory labeling, ensuring product stability and environmental safety.

Storage & Disposal Scope Official Regulatory Requirement
Labeled storage temperature requirements: This veterinary medicinal product does not require any special temperature storage conditions.
Child-protection storage requirements (if stated): The product must be kept out of the sight and reach of children.
Disposal instructions (as documented in government sources): The medicine should not be disposed of via wastewater or household waste; utilize take-back schemes in accordance with local requirements.

Connection to the overall storage/disposal profile: Regulatory documents define the storage by stating that no specialized temperature controls are necessary, thereby ensuring product stability under general conditions. The profile strictly mandates that the tablets be inaccessible to children. Furthermore, disposal instructions require that unused or expired product must be managed as pharmaceutical waste, prohibiting its release into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quanifen found in:

A-Z Index: